Zymeworks (ZYME)
(Real Time Quote from BATS)
$9.23 USD
+0.42 (4.77%)
Updated May 13, 2024 03:59 PM ET
After-Market: $9.25 +0.02 (0.22%) 4:14 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZYME 9.23 +0.42(4.77%)
Will ZYME be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
3 Top Stocks to Invest in for Amazing Earnings Acceleration
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Other News for ZYME
Zymeworks Breaks Below 200-Day Moving Average - Notable for ZYME
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Hold Rating on Zymeworks: Balancing Potential Rewards and Valuation Risks
Zymeworks price target lowered by $2 at Wells Fargo, here's why